AGL trades 9.7% above Wall Street's consensus target of $104.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AGL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 25 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 18, 2026, Agilon Health, Inc. (AGL) has a Wall Street consensus price target of $104.00, based on estimates from 25 covering analysts. With the stock currently trading at $115.20, this represents a potential downside of -9.7%. The company has a market capitalization of $1.92B.
Analyst price targets range from a low of $48.00 to a high of $146.00, representing a 94% spread in expectations. The median target of $114.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 9 analysts rating the stock as a Buy or Strong Buy,14 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, AGL trades at a trailing P/E of -19.2x. Analysts expect EPS to grow +61.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
CNCCentene Corp. | $35.8B | $72.55 | $75.43 | +3.9% | Buy | 13.8x | 44 |
HUMHumana Inc. | $53.2B | $443.34 | $470.42 | +6.1% | Hold | 48.4x | 44 |
CVSCVS Health Corp. | $109.5B | $85.81 | $109.89 | +28.1% | Buy | 10.7x | 41 |
ELVElevance Health Inc. | $94.1B | $433.93 | $466.69 | +7.5% | Buy | 14.9x | 38 |
MOHMolina Healthcare, Inc. | $11.5B | $221.21 | $216.73 | -2.0% | Buy | 42.1x | 39 |
OSCROscar Health, Inc. | $7.7B | $29.84 | $37.43 | +25.4% | Hold | 15.4x | 13 |
CLOVClover Health Investments, Corp. | $2.5B | $4.73 | $5.63 | +19.0% | Hold | 86.3x | 9 |
ALHCAlignment Healthcare, Inc. | $1.6B | $7.62 | $12.29 | +61.3% | Buy | — | 16 |
DOCSDoximity, Inc. | $5.8B | $31.11 | $27.73 | -10.9% | Hold | 23.1x | 24 |
UNHUnitedHealth Group Incorporated | $353.9B | $389.68 | $478.68 | +22.8% | Buy | 18.9x | 52 |
Quick answers to the most common questions about buying AGL stock.
Wall Street's consensus price target for AGL is $104, -9.7% from its current price of $115.2. The below-market target from 25 analysts suggests limited near-term appreciation.
AGL has a consensus rating of "Hold" based on 25 Wall Street analysts. The rating breakdown is mixed, with 14 Hold ratings making up the largest segment. The consensus 12-month price target of $104 implies -9.7% downside from current levels.
AGL's current price is $115.2 with a consensus target of $104 (-9.7% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $146 for AGL, while the most conservative target is $48. The consensus of $104 represents the median expectation. These targets typically reflect 12-month expectations.
AGL is heavily covered by Wall Street, with 25 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 14 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AGL stock forecast based on 25 Wall Street analysts shows a consensus price target of $104, with estimates ranging from $48 (bear case) to $146 (bull case). The median consensus rating is "Hold".
Analysts are cautious on AGL, with 2 Sell ratings and a price target of $104 (-9.7% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AGL analyst price targets range from $48 to $146, a 94% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $104 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.